GILDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
GILEAD SCIENCES, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$153.07−3.12 (-2.00%)
Close on Oct 19, 2026
- Market cap
- $190.27B
- P/E (TTM)
- –
- Dividend yield
- 2.06%
Share price
+$30.26 (+24.64%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.EarningsEx-dividend
GILEAD SCIENCES, INC. grew revenue 5.5% to $30.46B over the twelve months to Jun 30, 2026. Operating income fell 131.0% to -$2.50B, moving the operating margin from 27.9% to -8.2%. Free cash flow was $12.94B, up 38.1% from a year earlier.
Revenue
$30.46B
+5.5% vs. a year earlier
Operating income
-$2.50B
-131.0% vs. a year earlier
Free cash flow
$12.94B
+38.1% vs. a year earlier
EPS, diluted
-$2.67
-153.5% vs. a year earlier
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $190.27B
- P/E ratio
- –
- Price to sales
- 6.25
- Price to book
- 16.08
- Dividend yield
- 2.06%
- Free cash flow yield
- 6.80%
Fundamentals
- Revenue
- $30.46B
- Net income
- -$3.24B
- EPS, diluted
- -$2.67
- Free cash flow
- $12.94B
- Book value per share
- $9.52
- Diluted shares
- 1.24B
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
$30.46B+5.5% YoY
Gross profit
$24.24B+6.9% YoY
Operating income
-$2.50B-131.0% YoY
Net income
-$3.24B-151.3% YoY
EPS, diluted
-$2.67-153.5% YoY
Free cash flow
$12.94B+38.1% YoY
Reported periodTrailing twelve months